Business
Solésence develops and manufactures mineral-based active ingredients and branded skin-care products using proprietary surface-treatment technology.
Solésence converted double-digit mineral-skin-care growth into profit, but a distress-range balance sheet, flagged screen and rising inventory reserves qualify the apparent inflection.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 18.6%OK
- Profitability — Net income declined 57.7% to $1.79M from $4.235MWatch
- Cash flow — Operating cash flow turned negative at an outflow of $8.567M from $1.971MWatch
- Margins — Operating margin contracted 727 bps to 2.53%Watch
- Accounting — Profit inflection with inventory and statistical warningsWatch
- Insiders — 5 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as SOLESENCE, INC. reports it. History and quarterly detail are in the app.
- Product$61.8M
- Consumer Products$54.9M
- Personal Care Ingredients$6.3M
- Advanced Materials$857K
- Product and Service, Other$270K
Leadership changes
From SOLESENCE, INC.'s own filings, the day they're filed.
- Marc James · Director · appointmenteff. 2026-04-24
- Jess Jankowski · CEO · departureeff. 2025-12-02
- Mark E. Miller · member · appointment
Latest filings
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-08-19
- 8-K · Company announcement2026-07-10
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SOLESENCE, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.